Is it a 3 Musketeers Scenario?
Will Contrave Vote Bode Well for All Obesity Drugmakers?
WASHINGTON Investors in Orexigen Therapeutics Inc. Wednesday were not only bubbling over with excitement about an FDA panel's backing of the firm's obesity drug Contrave (naltrexone/bupropion) with the company's stock rocketing as high as 129 percent but shares of potential competitors Arena Pharmaceuticals Inc. and Vivus Inc. also were on fire, leaping as high as 20.5 percent and 19.5 percent, respectively.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.